Natural killer group 2 member D (NKG2D) receptor (NKG2D)

Cytokine-induced killer (CIK) cells are a specialized population of ex vivo expanded lymphocytes, primarily CD3+CD56+ cells, that possess potent, non-MHC-restricted anti-tumor activity. This activity is largely driven by the expression of Natural Killer (NK) activating receptors, with the Natural killer group 2 member D (NKG2D) receptor playing a central role in tumor recognition (Blood, 2010). NKG2D functions as a molecular sensor for cellular distress by binding to ligands such as MICA, MICB, and UL16-binding proteins (ULBPs), which are typically absent on healthy cells but highly expressed on malignant cells due to genomic instability or oncogenic transformation (Nature Reviews Cancer, 2008). Upon ligand engagement, NKG2D triggers the release of lytic granules containing perforin and granzymes, inducing apoptosis in the target tumor cell regardless of its HLA expression status (Journal of Hematology & Oncology, 2015). CIK cell therapy is currently employed in clinical settings as an adoptive immunotherapy for various cancers, often demonstrating a superior safety profile and lower risk of graft-versus-host disease compared to conventional donor lymphocyte infusions (Frontiers in Immunology, 2020). Ongoing research aims to optimize this interaction through the development of CAR-CIK cells and the use of pharmacological agents to upregulate ligand expression on resistant tumors (Cancer Gene Therapy, 2023).

Other names

KLRK1Killer cell lectin-like receptor subfamily K member 1CD314NK activating receptors on CIK cellsCIK cell tumor-recognition receptors

Activation of cytotoxic signaling pathways in CIK cells via the DAP10 adapter protein upon binding to stress-induced ligands (MICA/B, ULBPs) on tumor cells, resulting in the polarized release of lytic granules and tumor cell lysis (Frontiers in Immunology, 2020).